Peptide Therapy Under Trump Administration: What's Changed
Medically reviewed by Dr. Sarah Chen, PharmD, BCPS
Explore the significant changes in peptide therapy regulation during the Trump administration, including the 'Right to Try' Act and the FDA's increased scrutiny of compounding pharmacies. Learn how these shifts have impacted patient access to peptide treatments.
Navigating Peptide Therapy Under the Trump Administration: A New Era of Regulation and Access
The use of peptide therapies has surged in recent years, with many individuals turning to these compounds for a wide range of health and wellness benefits. This increased interest has brought greater scrutiny from regulatory bodies, particularly the U.S. Food and Drug Administration (FDA). The peptide therapy Trump administration landscape was marked by significant legislative and regulatory shifts that have had a lasting impact on the availability and accessibility of these treatments. This article will explore the key changes that occurred during this period, including the landmark "Right to Try" Act and the FDA's evolving stance on compounded peptides. For a broader overview of peptide therapies, you can visit our extensive peptide library.
The Shifting Sands of Peptide Regulation
Peptide therapies occupy a unique space in the medical world. While some are FDA-approved drugs, many others are used off-label or are available through compounding pharmacies. This has created a complex and often confusing regulatory environment for both patients and practitioners. The Trump administration's focus on deregulation in some areas, combined with a push for greater patient autonomy, led to a series of changes that have reshaped the peptide therapy landscape.
---
The specialists at TeleGenix can help you navigate the complexities of peptide therapy and determine if it's the right choice for you.
---
The "Right to Try" Act: A Landmark Shift in Experimental Treatment Access
In May 2018, President Donald J. Trump signed the Trickett-Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, commonly known as the "Right to Try" Act [1]. This federal law created a new pathway for terminally ill patients who have exhausted all approved treatment options to access certain unapproved, investigational drugs without needing to go through the FDA's traditional expanded access program. The law was championed as a way to give patients more control over their healthcare and provide hope to those with life-threatening conditions.
How "Right to Try" Impacted Peptide Therapy
While the "Right to Try" Act was not specifically aimed at peptide therapies, it had implications for their use. For patients with terminal illnesses who had exhausted other options, the law potentially opened a door to accessing investigational peptide-based treatments that were still in clinical trials. However, the law has several important limitations:
It only applies to drugs that have completed a Phase 1 clinical trial and are still under development.
The drug manufacturer is not obligated to provide the treatment.
The law does not require insurance companies to cover the cost of investigational treatments.
Despite these limitations, the "Right to Try" Act represented a significant philosophical shift in the balance between patient autonomy and FDA oversight. It signaled a willingness to consider alternative pathways to treatment access, a theme that would continue to play out in the regulation of peptide therapies.
FDA's Stance on Compounded Peptides: Increased Scrutiny and Enforcement
Compounding pharmacies have long played a crucial role in providing customized medications for patients with specific needs. This includes the compounding of peptide therapies that are not commercially available as FDA-approved drugs. During the Trump administration, the FDA continued to grapple with how to regulate this practice, balancing the need for patient access with concerns about safety and efficacy.
The 503A and 503B Framework
The FDA's regulation of compounding pharmacies is primarily governed by sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
503A pharmacies compound medications based on individual patient prescriptions. They are subject to state board of pharmacy oversight but are not required to follow full FDA good manufacturing practices (GMP).
503B outsourcing facilities can compound larger batches of medications without a prescription, but they must register with the FDA and adhere to GMP.
A 2023 analysis of FDA warning letters issued to 503A facilities between 2017 and 2021 found that a significant percentage of these pharmacies had issues with sterile compounding and were compounding drugs without valid prescriptions [2]. This increased scrutiny from the FDA during the Trump administration led to a more challenging environment for compounding pharmacies that were providing peptide therapies.
Comparison of Regulatory Status for Common Peptides
| Peptide | Regulatory Status | Considerations |
| :--- | :--- | :--- |
| Ipamorelin | Not FDA-approved for any indication | Often used for anti-aging and performance enhancement. Its availability through compounding pharmacies has been a subject of FDA scrutiny. |
| BPC-157 | Not FDA-approved for any indication | Popular for its purported healing and regenerative properties. The FDA has raised concerns about its safety and lack of clinical data. [3] |
| Sermorelin | FDA-approved for diagnostic use | Often used off-label for anti-aging and growth hormone optimization. Its use in compounding is generally considered permissible when prescribed by a licensed practitioner. |
| Tesamorelin | FDA-approved for HIV-associated lipodystrophy | A prescription drug that is not typically compounded. |
To see how different peptides stack up against each other, check out our peptide comparison tool.
The Impact on Patients and Practitioners
The regulatory changes and increased enforcement during the Trump administration had a mixed impact on patients and practitioners. While the "Right to Try" Act offered a new potential avenue for some patients, the FDA's crackdown on certain compounded peptides made it more difficult for others to access these therapies. Many practitioners found themselves in a challenging position, trying to navigate the complex legal and regulatory landscape while providing the best possible care for their patients. This is particularly true for those treating complex conditions where peptide therapies show promise.
Finding a Qualified Provider
Given the complexities of peptide therapy, it is crucial to work with a qualified healthcare provider who has experience in this area. A knowledgeable provider can help you understand the potential risks and benefits of different peptide therapies, determine if you are a good candidate for treatment, and source the medications from a reputable pharmacy. You can learn more about finding a provider in your area by visiting our TRT Near Me page.
---
The specialists at TeleGenix can help you navigate the complexities of peptide therapy and determine if it's the right choice for you.
---
The Future of Peptide Regulation: What to Expect
The regulation of peptide therapy is a constantly evolving field. The changes that occurred during the Trump administration have set the stage for ongoing discussions about the appropriate balance between patient access, innovation, and safety. As more research on peptide therapies becomes available, we can expect to see further shifts in the regulatory landscape. For now, it is essential for patients and practitioners to stay informed and to work together to ensure that these promising treatments are used safely and effectively.
For more information on peptide therapy, please visit our peptide therapy guide and our compounds library.
References
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any treatment.*
---